Trevi Therapeutics, Inc.
TRVI
$16.64
-$0.18-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.77% | 23.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.53% | 45.91% | |||
| Operating Income | -37.53% | -45.91% | |||
| Income Before Tax | -34.85% | -58.57% | |||
| Income Tax Expenses | 5.00% | -25.00% | |||
| Earnings from Continuing Operations | -34.91% | -58.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.91% | -58.63% | |||
| EBIT | -37.53% | -45.91% | |||
| EBITDA | -37.62% | -46.02% | |||
| EPS Basic | -21.41% | -58.39% | |||
| Normalized Basic EPS | -21.34% | -58.38% | |||
| EPS Diluted | -21.41% | -58.39% | |||
| Normalized Diluted EPS | -21.34% | -58.38% | |||
| Average Basic Shares Outstanding | 11.13% | 0.06% | |||
| Average Diluted Shares Outstanding | 11.13% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||